Evidence map›Paper›PMID 40000479›Full record

ArticleJournal of cancer research and clinical oncology2025

Liang Xie, Jialin Qin, Cuiping Song, Jianchun Yin, Ruixue Wu, Hong Chen, Yujie Dong, Nianfei Wang, Lei Chen, Bing Hong and 4 more

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. [International journal of molecular sciences · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Liang XieDepartment of Nuclear Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Jialin QinDepartment of Nuclear Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Cuiping SongDepartment of Nuclear Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Jianchun YinSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China.
Ruixue WuSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China.
Hong ChenDepartment of Nuclear Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Yujie DongSchool of Second Clinical Medical, Anhui Medical University, Hefei, 230032, Anhui, China.
Nianfei WangDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Lei ChenDepartment of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China.
Bing HongInstitute of Plasma Physics, Hefei Institutes of Physical Science, Chinese Academy of Sciences, HefeiAnhui, 230031, China.
Ni ChenSchool of Basic Medical Sciences, Anhui Medical University, Hefei, 230032, Anhui, China.
Peng LuInstitute of Plasma Physics, Hefei Institutes of Physical Science, Chinese Academy of Sciences, HefeiAnhui, 230031, China.
Fei LiDepartment of Nuclear Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. lifei007@139.com.
Xiaoxi PangDepartment of Nuclear Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. frankpang@foxmail.com.

Funding

Clinical Research Cultivation Program of The Second Affiliated Hospital of Anhui Medical University 2021LCYB08, 2020LCD14University Natural Science Research Project of Anhui Province 2023AH040380, KJ2021ZD0031
6 · The paper itself

Abstract

purposeGadolinium-neutron capture therapy (Gd-NCT) employs isotopically enriched Gadolinium (Gd) and thermal neutrons to selectively target cancer cells. This study investigated the targeting efficacy of METHODS AND

resultsWe developed

conclusions

Indexed as

GadoliniumNeutron Capture TherapyOrganometallic CompoundsProstatic NeoplasmsAnimalsCell Line, TumorHeterocyclic CompoundsHumansMagnetic Resonance ImagingMaleMiceMice, NudePositron Emission Tomography Computed TomographyRadiopharmaceuticalsTheranostic NanomedicineXenograft Model Antitumor AssaysGadoliniumgadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetateHeterocyclic CompoundsOrganometallic CompoundsRadiopharmaceuticalsMolecular imagingMRINeutron capture therapyPET/CTProstate cancerPSMA

Identifiers

PMID40000479
PMCPMC11861226

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.